<DOC>
	<DOCNO>NCT02382016</DOCNO>
	<brief_summary>24-week study evaluate efficacy safety macitentan treatment portopulmonary hypertension .</brief_summary>
	<brief_title>PORtopulmonary Hypertension Treatment wIth maCitentan â”€ randOmized Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>Main Male female least 18 year age Confirmed diagnosis portopulmonary hypertension Main Severe hepatic impairment Severe obstructive restrictive lung disease Pulmonary venoocclusive disease Systolic blood pressure ( SBP ) &lt; 90 mmHg Screening ALT/AST &gt; = 3 x ULN Bilirubin &gt; = 3 mg/dL Screening Any known factor disease might interfere treatment compliance , study conduct , interpretation result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>